Valuation: Mylan Inc

Market Cap 1.94TCr 1.7TCr 1.56TCr 1.46TCr 2.76TCr 1,85200Cr 2.8TCr 19TCr 7.29TCr 91TCr 7.3TCr 7.14TCr 3,13700Cr P/E 2026 *
61.1x
P/E 2027 * 26.4x
Enterprise Value 3.16TCr 2.77TCr 2.54TCr 2.37TCr 4.49TCr 3,01200Cr 4.56TCr 31TCr 12TCr 1,48100Cr 12TCr 12TCr 5,10200Cr EV / Sales 2026 *
2.14x
EV / Sales 2027 * 2.03x
Free-Float
92.23%
Yield 2026 *
3.05%
Yield 2027 * 3.13%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%+0.48%+55.50%+163.08% 1,08200Cr
+3.57%+3.29%+68.60%+61.03% 63TCr
+3.99%+3.05%+37.93%+93.37% 46TCr
+3.86%+1.64%+32.57%+24.89% 34TCr
-0.56%+0.96%+41.67%+39.35% 30TCr
-0.08%+1.30%+32.15%+44.48% 29TCr
-1.54%+2.81%-25.35%-39.61% 22TCr
+3.55%+4.41%+25.45%+66.28% 20TCr
+4.21%+2.65%+17.47%+71.11% 16TCr
Average +2.10%+4.58%+31.78%+58.22% 41.03TCr
Weighted average by Cap. +2.25%+5.53%+42.31%+83.31%

Financials

2026 *2027 *
Net sales 1.48TCr 1.29TCr 1.19TCr 1.11TCr 2.1TCr 1,40700Cr 2.13TCr 14TCr 5.54TCr 69TCr 5.55TCr 5.43TCr 2,38300Cr 1.5TCr 1.31TCr 1.21TCr 1.13TCr 2.14TCr 1,43200Cr 2.17TCr 15TCr 5.64TCr 70TCr 5.64TCr 5.52TCr 2,42500Cr
Net income 1.3Cr 1.14Cr 1.04Cr 97.33L 1.85Cr 123.75Cr 1.87Cr 13Cr 4.87Cr 61Cr 4.88Cr 4.77Cr 209.62Cr 50Cr 43Cr 40Cr 37Cr 71Cr 4.74TCr 72Cr 479.86Cr 186.55Cr 2.33TCr 186.75Cr 182.74Cr 8.02TCr
Net Debt 1.22TCr 1.07TCr 979.07Cr 912.61Cr 1.73TCr 1,16000Cr 1.76TCr 12TCr 4.57TCr 57TCr 4.57TCr 4.48TCr 1,96500Cr 1.1TCr 964.29Cr 886.18Cr 826.02Cr 1.57TCr 1,05000Cr 1.59TCr 11TCr 4.14TCr 52TCr 4.14TCr 4.05TCr 1,77900Cr
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-